CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference

  • Newly developed helper-free AAV packaging cell line provides unique solution for large-scale viral gene therapy vector production
  • Easy and stable production processes, independent of transient transfection or helper virus
  • Data from CEVEC’s successful proof-of-concept studies will be presented at the conference

Cologne, Germany, January 16, 2018

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will introduce a new solution for scalable stable viral vector production for gene therapy applications at the Phacilitate Cell & Gene Therapy World conference to be held January 22 – 25, 2018 in Miami, Florida, USA.